drugset / Trial / NCT03184324
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of DWP14012 compared to esomeprazole in the treatment of erosive gastroesophageal reflux disease classified as Los Angeles(LA) classification grades A to D.
Timeline
- Start
- 2017-08-28
- Primary completion
- 2018-04-18
- Completion
- 2018-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABEPRAZAN | Small molecule | 20 mg | Oral |
| Subject | ABEPRAZAN | Small molecule | 40 mg | Oral |
| Subject | ABEPRAZAN | Small molecule | 80 mg | Oral |
| Comparator | Esomeprazole | Small molecule | 40 mg | Oral |